Targeting FcγRI in autoimmune disease and anti-cancer therapy

In this project, we are characterizing a panel of new FcγRI (CD64) antibodies that were recently developed in our laboratory. It was long believed that this receptor was less relevant due to its high affinity and therefore engagement with monomeric IgG. However, recently we have shown that it is important for antibody therapy in cancer and autoimmune disease. With this unique panel of antibodies we can assess the importance of FcγRI in cancer and autoimmune diseases, and pave the way for therapeutic development.

Tosca Holtrop